{"id":254320,"date":"2012-08-09T22:10:48","date_gmt":"2012-08-09T22:10:48","guid":{"rendered":"http:\/\/www.eugenesis.com\/treating-drug-resistant-cancer-through-targeted-inhibition-of-sphingosine-kinase\/"},"modified":"2012-08-09T22:10:48","modified_gmt":"2012-08-09T22:10:48","slug":"treating-drug-resistant-cancer-through-targeted-inhibition-of-sphingosine-kinase","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biology\/treating-drug-resistant-cancer-through-targeted-inhibition-of-sphingosine-kinase.php","title":{"rendered":"Treating drug resistant cancer through targeted inhibition of sphingosine kinase"},"content":{"rendered":"<p><p>Public  release date: 9-Aug-2012  [ |   E-mail   |  Share    ]  <\/p>\n<p>    Contact: Dr. James Antoon    <a href=\"mailto:jantoon@tulane.edu\">jantoon@tulane.edu<\/a>    Society    for Experimental Biology and Medicine<\/p>\n<p>    Scientists at Tulane University School of Medicine, led by Dr.    James Antoon and Dr. Barbara Beckman, have characterized two    drugs targeting sphingosine kinase (SK), an enzyme involved in    cancer growth and metastasis. New treatments specifically    attacking cancer cells, but not normal ones, are critical in    the fight against cancer. The results, which appear in the July    2012 issue of Experimental Biology and Medicine,    demonstrate the role of SK in drug resistance and therapeutic    potential of SK inhibitors.  <\/p>\n<p>    \"Sphingosine kinase is a relatively new molecular target,\" says    Dr. Beckman \"In this study, we show that overexpression of SK    promotes resistance to first-line breast cancer therapies, such    as tamoxifen. We further found that treatment with the    sphingosine kinase inhibitors SKI-II and ABC294640 induced cell    death and blocked drug-resistant tumor growth without similar    effects in a model system representing relatively normal breast    cells.\"  <\/p>\n<p>    Molecular therapies, such as those targeting SK, have the    potential to improve treatment response rates while    simultaneously decreasing side effects. However, Dr. Antoon    cautions that \"while these results are promising, further study    is needed to fully understand the benefits and risks associated    with treating drug resistant cancer with these SK inhibitors.\"  <\/p>\n<p>    Dr. Steven R. Goodman, Editor-in-Chief of Experimental    Biology and Medicine said \"Dr. Antoon, Dr. Beckman and    colleagues present exciting results indicating the need for    further study of inhibitors of sphingosine kinase as promising    new cancer treatments\".  <\/p>\n<p>    ###  <\/p>\n<p>    Experimental Biology and Medicine is a journal dedicated    to the publication of multidisciplinary and interdisciplinary    research in the biomedical sciences. The journal was first    established in 1903.  <\/p>\n<p>    Experimental Biology and Medicine is the journal of the    Society of Experimental Biology and Medicine. To learn about    the benefits of society membership visit <a href=\"http:\/\/www.sebm.org\" rel=\"nofollow\">http:\/\/www.sebm.org<\/a>. If you are    interested in publishing in the journal please visit <a href=\"http:\/\/ebm.rsmjournals.com\" rel=\"nofollow\">http:\/\/ebm.rsmjournals.com<\/a>.  <\/p>\n<\/p>\n<p>Go here to see the original:<br \/>\n<a target=\"_blank\" href=\"http:\/\/www.eurekalert.org\/pub_releases\/2012-08\/sfeb-tdr080912.php\" title=\"Treating drug resistant cancer through targeted inhibition of sphingosine kinase\">Treating drug resistant cancer through targeted inhibition of sphingosine kinase<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Public release date: 9-Aug-2012 [ | E-mail | Share ] Contact: Dr. James Antoon <a href=\"mailto:jantoon@tulane.edu\">jantoon@tulane.edu<\/a> Society for Experimental Biology and Medicine Scientists at Tulane University School of Medicine, led by Dr.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biology\/treating-drug-resistant-cancer-through-targeted-inhibition-of-sphingosine-kinase.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[577690],"tags":[],"class_list":["post-254320","post","type-post","status-publish","format-standard","hentry","category-biology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/254320"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=254320"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/254320\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=254320"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=254320"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=254320"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}